Ankylosing Spondylitis
Ankylosing spondylitis (AS) is a type of chronic inflammatory arthritis primarily affecting the spine and pelvis, leading to pain, stiffness, and potential fusion of the vertebrae, often accompanied by eye and bowel problems. It involves genetic and environmental factors, with a strong association to the HLA-B27 antigen, and is diagnosed through symptoms, medical imaging, and blood tests.
Health Outcomes
- Altered Serum Immune Protein Levels
- Decreased TNFα Levels
- Elevated Interleukin-17 Levels
- Elevated Serum Metabolites in Response to Inflammation
- Enhanced Immunoregulatory Molecule Activity
- Enhanced Innate Immune Response
- Improved Antioxidant and Anti-Inflammatory Response
- Improved Bone Health
- Improved Bone Preservation
- Improved Clinical Disease Activity
- Improved Connective Tissue Attachment Levels
- Improved Disease Activity Index Score
- Improved Joint Function
- Improved Orthopedic Function
- Improved Pain Score
- Improved Patient Global Assessment
- Improved Physician Global Assessment
- Improved Stiffness
- Improved Symptom Control in Degenerative Joint Disease
- Increased Anti-Inflammatory Levels
- Increased Anti-Osteoclastogenic Cytokine Production
- Increased Bone Volume
- Increased IL-12 Levels
- Increased IL-17 Levels
- Increased Inflammatory Mediator Production
- Increased Inflammatory Response
- Increased Lumbar Spine Bone Mineral Density
- Increased Spinal Fusion Rate
- Increased T Cell Activation
- Increased TNF-alpha Levels in Macrophages
- Increased Th1-Associated Cytokine Release
- Increased Th17 Polarization
- Increased Tumor Necrosis Factor-Alpha Production by Dendritic Cells
- Inflammatory Disease Protection
- Matured Antigen-Presenting Cells
- Modulated Humoral Inflammation
- No Change in C-Reactive Protein
- No Significant Change in Tumor Necrosis Factor Alpha Levels
- Prevention and Treatment of Inflammatory Diseases
- Reduced Aggravation of Chronic Inflammation
- Reduced Arthritis Incidence
- Reduced Arthritis Score
- Reduced Arthritis Symptoms
- Reduced Bone Erosion
- Reduced C-Reactive Protein Levels
- Reduced Clinical Symptoms of Arthritis
- Reduced Disease Activity
- Reduced Disease Activity Index (DAI) Levels
- Reduced Disease Activity Index Scores
- Reduced IL-17 Production in Splenocytes
- Reduced Inflammation
- Reduced Inflammatory Cytokines (TNF-α, IFN-γ, IL-6)
- Reduced Inflammatory Mediators
- Reduced Inflammatory Response to Inflammatory Stimulus
- Reduced Joint Damage
- Reduced Joint Inflammation
- Reduced Joint Swelling
- Reduced Joint Tenderness
- Reduced Levels of Interleukin-17
- Reduced Levels of Receptor Activator of Nuclear Factor-kappa B Ligand
- Reduced Pain During Movement
- Reduced Pain Intensity
- Reduced Pain Levels
- Reduced Pain Scale
- Reduced Plasma Tumor Necrosis Factor-α Levels
- Reduced Pro-Inflammatory Immune Activity
- Reduced Pro-inflammatory Gene Transcription
- Reduced Proinflammatory Factor Levels
- Reduced Risk of Chronic Inflammatory Diseases
- Reduced Serum TNF-α Levels
- Reduced Serum Tumor Necrosis Factor-α
- Reduced Severity of Symptoms Per Day
- Reduced Stiffness
- Reduced Swelling
- Reduced Synovial Infiltration
- Reduced TH17 Response
- Reduced TNF Production
- Reduced TNF-alpha Level
- Reduced TNF-α Concentration
- Reduced TNF-α Levels
- Reduced TNF-α Secretion
- Reduced TNF-α Signaling
- Reduced Tender Joint Count
- Reduced Time to Relief of Lower Back Pain
- Reduced Tumor Necrosis Factor Alpha
- Reduced Tumor Necrosis Factor Alpha Production
- Reduced Tumor Necrosis Factor-alpha Level
- Reduced Tumor Necrosis Factor-α (TNF-α)
- Reduced Tumor Necrosis Factor-α Levels
- Reduced hsCRP Level
- Safe Drug Administration
- Stable Inflammatory Responses
- Suppressed TNF-α Induced Genes
- Unchanged Body Weight